Trials / Completed
CompletedNCT00233532
Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)
A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naïve and Concurrently Treated Hypertensive Patients (TRAIL)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,000 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trandolapril | 0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks). |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-06-01
- First posted
- 2005-10-06
- Last updated
- 2008-07-22
Source: ClinicalTrials.gov record NCT00233532. Inclusion in this directory is not an endorsement.